FDA Drug Information Updates
Experts from the U.S. Food and Drug Administration (FDA) discuss important new drug information as well as urgent insights about approved drug products.
Episodes 1-15 of 47
The FAERS Public Dashboard and its Value to the Pharmaceutical Industry
FDA Drug Information UpdatesThe FAERS Public Dashboard and its Value to the Pharmaceutical Industry
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
FDA Drug Information UpdatesFDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
FDA’s Role in Foreign Drug Manufacturing
FDA Drug Information UpdatesFDA’s Role in Foreign Drug Manufacturing
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
Project Oncology®FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Drug Information UpdatesFDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
FDA Drug Information UpdatesFDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
The FDA's Adverse Event Reporting System (FAERS) Public Dashboard
FDA Drug Information UpdatesThe FDA's Adverse Event Reporting System (FAERS) Public Dashboard
FDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
FDA Drug Information UpdatesFDA D.I.S.C.O.: L-Glutamine for Sickle Cell Disease
FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
Project Oncology®FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer
FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
Project Oncology®FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer
FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval
Project Oncology®FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval
FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma
Project Oncology®FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma
FDA D.I.S.C.O.: Niraparib in Ovarian Cancer
Project Oncology®FDA D.I.S.C.O.: Niraparib in Ovarian Cancer
FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
FDA Drug Information UpdatesFDA D.I.S.C.O.: Rucaparib in Ovarian Cancer
Introducing FDA's Drug Information Soundcast in Clinical Oncology (DISCO)
FDA Drug Information UpdatesIntroducing FDA's Drug Information Soundcast in Clinical Oncology (DISCO)
